SEC Filing Summary
Filing mismatch: The supplied filing is Venaxis, Inc.’s Form 10-Q for the quarter ended June 30, 2013, filed August 7, 2013. It is not a Riot Platforms, Inc. filing. The summary below describes the filing text provided.
Business context and reporting period
Venaxis was developing APPY 1, a diagnostic test for acute appendicitis, and had received CE marking in Europe in January 2013. Its primary focus was clinical development and pursuing FDA clearance, alongside early European commercialization. The company had suspended antigen production and reported no product sales in the first half of 2013.
Key financial metrics
| Metric | Three months ended June 30, 2013 | Six months ended June 30, 2013 |
|---|---|---|
| Product sales | $0 | $0 |
| License fee revenue | $21,249 | $39,904 |
| Operating expenses | $3.15 million | $5.99 million |
| Operating loss | $3.13 million | $5.95 million |
| Net loss | $3.14 million | $5.95 million |
| Basic and diluted loss per share | $0.21 | $0.48 |
At June 30, 2013, cash and cash equivalents were $9.74 million and short-term investments were $10.26 million, or approximately $19.99 million combined. Working capital was $18.08 million; total assets were $24.10 million; total liabilities were $5.49 million; and stockholders’ equity was $18.61 million. Total notes and other obligations were $2.37 million, principally mortgage debt. The mortgage was refinanced in May 2013; the bank portion carried a fixed 3.95% rate and a five-year balloon maturity, while the SBA portion bore 5.86% interest.
For the first half of 2013, operating cash use was $4.36 million, investing cash use was $9.17 million, and financing provided $12.28 million. Financing included $12.97 million of net stock-offering proceeds. Cash and cash equivalents declined by $1.24 million to $9.74 million; the investing outflow primarily reflected purchases of short-term investments, not simply operating expenditure. The filing does not present a useful product gross margin for 2013 because product sales and cost of sales were both zero.
Material changes versus prior comparable periods
- First-half net loss increased to $5.95 million from $4.25 million in 2012; second-quarter net loss rose to $3.14 million from $2.31 million.
- First-half research and development expense increased 106% to $3.21 million, chiefly due to APPY 1 clinical-trial activity. Direct APPY 1 development and related clinical and regulatory costs were approximately $2.21 million, versus $0.81 million in the prior-year period.
- First-half selling, general and administrative expense increased 7% to $2.78 million. Higher commercialization and marketing costs were partly offset by lower compensation.
- Product sales fell to zero from $34,516 in the first half of 2012 and $27,241 in the second quarter of 2012, reflecting the decision to suspend antigen production.
- Shares outstanding increased from 9.95 million at December 31, 2012 to 21.45 million at June 30, 2013 following the May public offering of 11.5 million shares at $1.25 each. The offering also included warrants to purchase up to 4.025 million shares at $1.36.
- Debt declined from $3.05 million at year-end 2012 to $2.37 million at June 30, 2013, including repayment of the Novartis termination obligation and other obligations; the commercial mortgage was refinanced.
Outlook, risks, contingencies, and unusual items
- Management expected continuing near-term operating losses and believed available working capital would fund estimated needs through the remainder of 2013 and into 2014. The filing also cautioned that further capital could be required, particularly for FDA clearance and initial U.S. and European commercialization; unavailable financing could force reduced research and development or cessation of operations.
- Near-term priorities included APPY 1 clinical-trial enrollment and FDA clearance steps, European commercialization following CE marking, partnership or licensing opportunities, and cost control. Capital expenditures for the remainder of 2013 were estimated at $75,000–$125,000.
- Key risks included clinical-trial delays or unsuccessful results, failure to obtain FDA clearance, limited market adoption or reimbursement, competition, manufacturing and supplier issues, and dependence on additional financing. The filing stated that the company expected operating losses at least until 2015.
- A securities class action dismissed without prejudice in 2012 was on appeal; oral argument was scheduled for September 26, 2013. Management considered the claims meritless and intended to continue defending the case.
- The animal-health license agreement could provide future milestones of up to $1.1 million, plus up to an additional $2 million for additional licensed products, and low-double-digit royalties, contingent on milestones and product sales. These amounts were not guaranteed revenue.
- Management said disclosure controls and procedures were effective as of June 30, 2013, and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the intended issuer and period: this source is Venaxis, Inc., not Riot Platforms, Inc.
- Review APPY 1 trial progress, enrollment, clinical results, and FDA pathway and timing; the filing provides no assurance of clearance.
- Assess the cash runway against the stated funding outlook, ongoing operating cash use, and anticipated clinical and commercialization spending.
- Review dilution from the May offering and potential exercise of 4.025 million warrants, as well as the mortgage balloon maturity and repayment schedule.
- Track the securities-litigation appeal and whether the animal-health licensee achieves milestones that could trigger contingent payments.